On July 10, 3SBio rose 5.53% in regular trading, reaching HKD 17.98/share, with turnover of HKD 369 million. The stock advanced alongside a broad biotech sector rally, with PEGBIO surging 41.23%, Remegen up 7.14%, Akeso up 5.39%, Innovent Bio up 4.69%, and BeiGene up 2.64%.

The move comes amid multiple recent positive corporate actions. In June, 3SBio repurchased approximately 8.52 million shares at prices between HKD 15.52 and HKD 16.00, holding them as treasury stock. The company also declared a final dividend of HKD 0.25 per share payable on August 4. Additionally, Chairman Lou Jing increased his stake by 516,000 shares in early June at HKD 15.25 per share, while institutional investor Hui Tian Fu Fund raised its holding to 7% of issued shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)